Journal of substance use and addiction treatment最新文献

{"title":"Feasibility and acceptability of a contingency management program for stimulant use disorder in a pallet shelter community for homeless-experienced veterans","authors":"Michael Hsu ,&nbsp;Talia Panadero ,&nbsp;Nisha Choothakan ,&nbsp;Mikayla O. Castellon ,&nbsp;Gregory Gee ,&nbsp;Edwin Jacobo ,&nbsp;Erin P. Finley ,&nbsp;James R. McKay ,&nbsp;Peter Capone-Newton ,&nbsp;Larissa J. Mooney ,&nbsp;Sonya Gabrielian","doi":"10.1016/j.josat.2025.209771","DOIUrl":"10.1016/j.josat.2025.209771","url":null,"abstract":"<div><h3>Background</h3><div>Stimulant use disorder (StUD) is a leading cause of overdose and death among homeless-experienced Veterans (HEVs). Contingency management (CM), a behavioral intervention offering rewards for stimulant abstinence, is the most effective psychosocial treatment for StUD. However, CM remains underutilized and understudied in homeless service settings. We piloted CM at a novel transitional pallet shelter community for HEVs and assessed the intervention's feasibility and acceptability.</div></div><div><h3>Methods</h3><div>We implemented a 12-week, on-site CM program at a pallet shelter community—comprised of locked, private “tiny homes” alongside on-site case management and health services—at the Veterans Affairs Greater Los Angeles. Veterans with a history of StUD were eligible to participate in twice-weekly urine drug screening (UDS), with voucher-based rewards for stimulant-negative results. Mixed methods were used to evaluate CM's feasibility and acceptability, including quantitative measures of attendance and abstinence and qualitative interviews with participating Veterans (n = 10) and staff (n = 6).</div></div><div><h3>Results</h3><div>Among 26 enrolled Veterans, average session attendance was 32 % and 49 % of UDS samples were negative for stimulants. Qualitative findings identified several factors that supported CM's acceptability, including perceptions that CM was accessible, structured, and supportive; helped meet immediate needs through monetary rewards; and enhanced engagement with health services. Reported barriers included concerns about privacy, stigma, and perceptions of insufficient rewards.</div></div><div><h3>Conclusion</h3><div>This pilot showed initial Veteran engagement and positive Veteran and staff attitudes toward implementing CM at CTRS, though feasibility and acceptability may be enhanced by addressing concerns regarding privacy, stigma, accessibility, rewards, and integrated psychotherapeutic support.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"177 ","pages":"Article 209771"},"PeriodicalIF":1.9,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bacterial infections risk scale for injection drug use: A brief screener to identify skin and soft tissue infection risk for people who inject drugs","authors":"Leonardo Dominguez Gomez ,&nbsp;Ashly E. Jordan ,&nbsp;Izza Zaidi ,&nbsp;Hannah Helmy ,&nbsp;Alex Harocopos","doi":"10.1016/j.josat.2025.209767","DOIUrl":"10.1016/j.josat.2025.209767","url":null,"abstract":"<div><h3>Introduction</h3><div>Skin and soft tissue infections (SSTI) and severe injection-related infections (SIRI) cause serious morbidity among people who inject drugs (PWID). Data suggest that specific injection practices associate with a higher risk of developing SSTI/SIRI, and that a brief screening tool may help identify at-risk individuals. This study examines injection drug use behaviors and SSTI/SIRI experiences among a sample of PWID in New York City (NYC). In particular, the analysis explores the potential utility of the bacterial infections risk scale for injection drug use (BIRSI) in identifying people at risk for developing SSTI/SIRI in a non-hospitalized population of PWID.</div></div><div><h3>Methods</h3><div>This study examines associations between sociodemographic factors, healthcare system usage, injection practices, and the seven-item BIRSI instrument in relation to reported past 90-day SSTI/SIRI among a subset of respondents who reported past 90-day injection drug use (146 total respondents). Each respondent received a composite score for the BIRSI instrument by adding a point for each reported behavior. Analyses examine the association between select factors and reporting ≥1 SSTI/SIRI in the past 90 days.</div></div><div><h3>Results</h3><div>Among participants, 55.5 % identified as Hispanic and 30.1 % as female. The mean age was 44.6 years and 32.2 % had stable housing. The prevalence of reported past 90-day SSTI/SIRI was 24.7 %. Unadjusted univariate models showed age (prevalence ratio, PR: 0.97, 95 % CI: 0.94, 0.99), receptive syringe sharing (RSS) (PR: 2.91, 95 % CI: 1.69, 4.88) or using other people's previously used (non-syringe) injection equipment (PR: 2.61, 95 % CI: 1.53, 4.45), and a higher BIRSI composite score (PR: 1.33, 95 % CI, 1.34, 1.56) to associate with reporting of past 90-day SSTI/SIRI. Further modeling showed that a higher BIRSI score, exclusive of other injection related behaviors, was associated with self-reported SSTI/SIRI (adjusted PR: 1.35, 95 % CI: 1.13, 1.62) when controlling for age, sex, race, and housing status.</div></div><div><h3>Conclusion</h3><div>Findings suggest the BIRSI instrument may be a useful, brief tool to identify individuals at higher risk of developing SSTI/SIRI among non-hospitalized PWID. Using the BIRSI instrument can help programs and staff serving PWID to implement strategies to reduce SSTI/SIRI risk among their participants, such as wound prevention and care interventions.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"178 ","pages":"Article 209767"},"PeriodicalIF":1.9,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144769429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospital readmissions and emergency department encounters among patients who initiate medications for opioid use disorder during hospitalization: Comparison of patients with and without co-occurring methamphetamine use","authors":"Kevin A. Hallgren ,&nbsp;Elizabeth Speaker ,&nbsp;Elenore P. Bhatraju ,&nbsp;Matthew Iles-Shih ,&nbsp;Devin N. Kennedy ,&nbsp;Alexander J. Gojic ,&nbsp;Charissa Fotinos ,&nbsp;Joseph O. Merrill ,&nbsp;Judith I. Tsui","doi":"10.1016/j.josat.2025.209765","DOIUrl":"10.1016/j.josat.2025.209765","url":null,"abstract":"<div><h3>Background</h3><div>Many hospitals initiate medications for opioid use disorder (MOUD), which are associated with reduced opioid use and fewer readmissions. Among people who use opioids, co-occurring methamphetamine use is increasingly prevalent and is associated with worse health and treatment outcomes. This study evaluated the frequency of hospital readmissions and emergency department (ED) encounters over a 6-month period after MOUD was initiated in a hospital setting. It was hypothesized that methamphetamine use within the 30 days prior to hospital admission would be associated with increased risk for hospital readmissions and ED encounters.</div></div><div><h3>Methods</h3><div>The sample included patients aged 18–64 with Title XIX Medicaid coverage who were admitted to a large, urban, public, university-affiliated hospital and initiated on MOUD by an addiction consult service between May 2019 and December 2021. Hospital readmissions and ED encounters were identified over 6 months after the index hospitalization using Medicaid claims. Patients self-reported past 30-day methamphetamine use during structured interviews. Cox proportional hazards models tested whether time to first readmission or first ED encounter differed for patients with and without recent methamphetamine use, adjusting for demographics and clinical covariates.</div></div><div><h3>Results</h3><div>Of 690 hospitalized patients initiating MOUD, 404 met study inclusion criteria (41 % unhoused, 56 % with methamphetamine use). Within 6 months after the index hospitalization, 35 % of patients had at least one hospital readmission and 54 % had at least one ED encounter. Hospitalization and ED incidence risks and event rates did not significantly differ for patients with and without methamphetamine use. In survival analyses, methamphetamine use was not associated with earlier hospital readmission (aHR = 0.98, 95 % CI: 0.70–1.35) or ED encounter (aHR = 0.90, 95 % CI: 0.67–1.20). Among patients with methamphetamine use, receiving buprenorphine (vs. methadone) was associated with earlier time to first ED encounter (aHR = 1.64, 95 % CI: 1.13–2.40, <em>p</em> = 0.01).</div></div><div><h3>Conclusions</h3><div>This study did not observe a significant association between methamphetamine use and risk of hospital readmission or ED encounters up to 6 months after initiation of MOUD in the hospital. Frequent hospital readmissions and ED encounters after discharge highlight the need for research on drivers of acute care utilization and interventions that better serve patients who initiate MOUD in hospital settings.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"177 ","pages":"Article 209765"},"PeriodicalIF":1.9,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144765874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retention rates and cost-effectiveness of telehealth vs. in-person buprenorphine treatment for opioid use disorder (OUD)","authors":"Rana Saad ,&nbsp;Melissa H. Roberts ,&nbsp;Julie G. Salvador ,&nbsp;Snehal R. Bhatt ,&nbsp;Matthew E. Borrego","doi":"10.1016/j.josat.2025.209764","DOIUrl":"10.1016/j.josat.2025.209764","url":null,"abstract":"<div><h3>Background</h3><div>Management of opioid use disorder (OUD) has evolved with integration of telehealth, particularly during COVID-19. This study evaluated effectiveness (retention to therapy) and cost-effectiveness of office-based versus telehealth buprenorphine treatment for OUD.</div></div><div><h3>Methods</h3><div>Retrospective chart review included 135 buprenorphine-treated patients at a New Mexico addiction and substance abuse program. Patients were categorized by treatment modality (office-based vs. telehealth). Retention, the effectiveness measure, was defined as continuous OUD treatment for ≥180 days. Logistic regression estimated odds ratios (ORs) and 95 % confidence intervals (CIs) for retention, controlling for demographics. Incremental cost-effectiveness ratios (ICERs) were calculated for direct medical, direct non-medical (transportation), and indirect costs (productivity losses) from a societal perspective.</div></div><div><h3>Results</h3><div>Analyses showed no statistically significant difference in retention between office-based (51 %) and telehealth (42 %) modalities (p &gt; 0.05). Males were less likely to remain in treatment (OR = 0.48 [95 % CI: 0.24–0.96], p = 0.04). Female retention rates were high (58 % in both modalities). Male rates were lower for office-based (45 %) and telehealth (34 %). The ICER analysis indicated that office-based modalities incurred additional costs of $3750 per 1 % increase in retention compared to telehealth, suggesting higher overall costs for retained patients in the office-based modality.</div></div><div><h3>Conclusion</h3><div>OUD patient retention rates were not significantly different between treatment modalities. However, office-based treatment incurred higher costs, emphasizing telehealth's potential as a cost-effective alternative. Future research should explore long-term outcomes, sex differences in treatment adherence, and the integration of telehealth into standard practice to enhance resource allocation and treatment accessibility.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"177 ","pages":"Article 209764"},"PeriodicalIF":1.9,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144765875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"More than a medicine: Personal insights on mat, stigma, and the road to recovery","authors":"Michael Minauro ,&nbsp;Nili Gesser","doi":"10.1016/j.josat.2025.209770","DOIUrl":"10.1016/j.josat.2025.209770","url":null,"abstract":"<div><div>Medication-assisted treatment (MAT) is often misunderstood and stigmatized, despite its proven effectiveness in supporting recovery from opioid use disorder. This manuscript presents the lived experience of Michael, who navigated addiction, relapse, and recovery with the help of MAT. Through an in-depth interview, Michael shares his journey from early substance use to multiple attempts at sobriety, highlighting the critical role of MAT in stabilizing his life.<span><span>¹</span></span> His story challenges common misconceptions about MAT, both from the general public and recovery communities. Michael’s experiences underscore the systemic barriers within MAT clinics, including outdated regulations and inadequate patient support, which can hinder recovery. He also reflects on the importance of advocacy, professionalization within treatment settings, and the need for universal behavioral health coverage. By shedding light on these challenges and successes, this narrative provides valuable insights for individuals in recovery, service providers, and policymakers seeking to improve access to and perceptions of MAT. Ultimately, this work affirms that MAT is more than just a medical intervention— it is a tool for reclaiming stability, purpose, and dignity in the face of addiction.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"177 ","pages":"Article 209770"},"PeriodicalIF":1.9,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144748825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cocaine Use Disorder in German outpatient addiction care - A trend analysis","authors":"Carlotta Riemerschmid ,&nbsp;Eva Hoch ,&nbsp;Charlotte E. Wittekind ,&nbsp;Advisory Board of the German Addiction Care Statistical Service ,&nbsp;Larissa Schwarzkopf","doi":"10.1016/j.josat.2025.209769","DOIUrl":"10.1016/j.josat.2025.209769","url":null,"abstract":"<div><h3>Background</h3><div>Cocaine is more readily available than ever in Europe, leading to rising consumption rates and an increasing demand for treatment of Cocaine Use Disorder (CoUD) in Germany. This study examines the impact of these trends on the outpatient addiction care setting in Germany by analyzing national trends in the demand for CoUD-related care and the sociodemographic characteristics of clients entering outpatient addiction care facilities (OACF) with a primary diagnosis of CoUD between 2001 and 2023.</div></div><div><h3>Methods</h3><div>Data were derived from the German Addiction Care Statistical Service (DSHS), which annually aggregates data from OACFs across Germany. Joinpoint regression analysis assessed trends in the demand for CoUD-related care, the proportion of first-time admissions, and sociodemographic variables (age, gender, education level, employment status). The trends for CoUD were compared to those of individuals entering care with another primary substance use disorder (SUD).</div></div><div><h3>Results</h3><div>The proportion of CoUD-related care episodes increased significantly from 1.8 % in 2001 to 4.4 % in 2023 in relation to the entire caseload, and to 8.2 % among SUDs (2001: 1.9 %). During this period, the CoUD client population became older, more educated (high education level: 4.7 % in 2001 vs. 23.4 % in 2023), and more frequently employed (33.6 % in 2009 vs. 53.7 % in 2023). The proportion of women remained relatively stable, with a slight increase from 12.9 % in 2001 to 13.5 % in 2023. First-time admissions for CoUD decreased overall but showed a significant increase from 2012 onward (2012: 35.9 %, 2023: 40.3 %).</div></div><div><h3>Conclusion</h3><div>CoUD is becoming increasingly relevant within German OACFs, with the care-seeking population shifting towards a profile characterized by middle age, higher education, and employment. In consequence, pre-existing programs for the care and support of individuals with CoUD may need to be adapted to enhance treatment success. Early interventions in occupational and educational settings may offer a promising approach. As our results seem to predominantly reflect CoUD caused by problematic powder cocaine use, more attention should also be given to individuals with problematic crack cocaine use, whose treatment needs and sociodemographic characteristics may differ.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"178 ","pages":"Article 209769"},"PeriodicalIF":1.9,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144762562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimates of first-year OTC naloxone sales in four U.S. states with high rates of opioid overdose deaths: KY, MA, NY, OH","authors":"Doris G. Gammon ,&nbsp;Jennifer Gaber ,&nbsp;McKinley Saunders ,&nbsp;Gary A. Zarkin","doi":"10.1016/j.josat.2025.209762","DOIUrl":"10.1016/j.josat.2025.209762","url":null,"abstract":"<div><h3>Introduction</h3><div>In March 2023, the U.S. Food and Drug Administration approved naloxone nasal spray for over-the-counter (OTC) sale, creating a direct-to-consumer path that can increase access.</div></div><div><h3>Methods</h3><div>We utilized weekly NielsenIQ (NIQ) retail sales data of OTC naloxone for local areas within Kentucky (KY), Massachusetts (MA), New York (NY), and Ohio (OH) during the week ending 9/9/2023 to week ending 4/27/2024, for sales occurring in physical stores (e.g., grocery, pharmacy). We analyzed the percentage of stores selling, average price per kit, and sales. We assessed patterns in local sales by a Social Deprivation Index accounting for poverty, housing, transit, education, and employment.</div></div><div><h3>Results</h3><div>The brand Narcan made up approximately 99 % of all recorded OTC naloxone sales from September 2023 through April 2024. Weekly sales of OTC naloxone in KY, MA, NY, and OH spiked initially in September and October 2023, and stabilized through April 2024. The average price per OTC naloxone kit was $45 across states and brand. Between 5.0 % and 8.6 % of NIQ participating stores in each state sold OTC naloxone. A large proportion of local areas in three states demonstrated high social deprivation and low OTC naloxone sales.</div></div><div><h3>Conclusions</h3><div>OTC naloxone increases access, though the price may deter people with low income, as evidenced by our findings of lower sales among areas with high social deprivation, emphasizing the importance of naloxone access laws, opioid education and naloxone distribution programs, and Medicaid coverage. OTC naloxone creates a new channel for market penetration, satisfying a previously untapped demand, and supports naloxone saturation.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"178 ","pages":"Article 209762"},"PeriodicalIF":1.9,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144762563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patching holes and bridging gaps: Implementing Law Enforcement-Assisted Diversion (LEAD) in resource-scarce environments","authors":"Meret Hofer ,&nbsp;Reah Siegel ,&nbsp;Michele Easter ,&nbsp;Melissia Larson ,&nbsp;Allison Gilbert","doi":"10.1016/j.josat.2025.209751","DOIUrl":"10.1016/j.josat.2025.209751","url":null,"abstract":"<div><h3>Introduction</h3><div>Law Enforcement Assisted Diversion (LEAD) is a pre-arrest diversion program that allows police officers to refer individuals to LEAD's harm reduction case management services in lieu of arrest for most low-level, non-violent criminalized behaviors. The program assesses participants' needs for resources and services and facilitates referrals and ongoing support to meet these needs. In this qualitative study, we examine the influence of service availability and accessibility on the implementation of North Carolina's LEAD programs.</div></div><div><h3>Methods</h3><div>We conducted in-depth, semi-structured interviews with 49 participants across four well-established LEAD sites, including LEAD partners (<em>n</em> = 27) and LEAD participants (<em>n</em> = 22). We analyzed the data using a blended inductive/deductive coding strategy.</div></div><div><h3>Findings</h3><div>Participants' narratives highlighted several important challenges related to service provision and linkage in communities with a dearth of service options. Findings were captured in four main themes. First, in some communities, certain resources and services were completely unavailable. Second, even when community-based resources and services were available, they were often perceived as inaccessible by participants for a variety of reasons. Third, LEAD programs and staff worked intensely and flexibly to increase access to community-based resources and services. Finally, there was widespread agreement that resource scarcity disrupted the continuum of care, thereby causing some participants to disengage from LEAD and related services as their readiness for change fluctuated.</div></div><div><h3>Conclusions</h3><div>The efficacy of diversion programs, including LEAD, depends not only on their high-quality implementation and fidelity to existing models, but also on successful coordination and linkage to a range of comprehensive, easily accessible and sustainable community-based resources and services. When community-based resources are unable to meet basic needs and support the continuum of care for people with substance use disorders, LEAD staff and participants will struggle to meet expectations and programs will be unlikely to optimize outcomes.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"176 ","pages":"Article 209751"},"PeriodicalIF":0.0,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144595410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What is necessary for implementation science to actually improve the state of addiction treatment and research?","authors":"Mark P. McGovern ,&nbsp;Hélène Chokron Garneau ,&nbsp;Heather J. Gotham ,&nbsp;Fernanda S. Rossi","doi":"10.1016/j.josat.2025.209753","DOIUrl":"10.1016/j.josat.2025.209753","url":null,"abstract":"","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"176 ","pages":"Article 209753"},"PeriodicalIF":1.9,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Journal of substance use and addiction treatment formal and informal substance use treatment utilization amongst Asian Americans","authors":"Christopher Villongco ,&nbsp;Benjamin G. Druss","doi":"10.1016/j.josat.2025.209754","DOIUrl":"10.1016/j.josat.2025.209754","url":null,"abstract":"<div><h3>Introduction</h3><div>Asian Americans (AA) in need of treatment for alcohol or substance use utilize substance use treatment at lower rates than all other races/ethnicities. This study tested if the lack of utilization is offset by greater informal substance use treatment utilization.</div></div><div><h3>Methods</h3><div>Analysis utilized pooled data from 2015 to 2019 National Survey of Drug Use and Health (NSDUH) in individuals aged ≥18. Unadjusted proportions, confidence intervals, and adjusted multivariate logistical regression examined the relationship of race/ethnicity (Asian, White, Black, and Hispanic) and substance use treatment in individuals with 12-month substance/alcohol use or AUD/SUD. Classifications of treatment were formal (doctor's office, mental health center, hospital, rehabilitation facility) or informal (self-help group, home/family/friends, school/college, or Church/religious/spiritual influence).</div></div><div><h3>Results</h3><div>AA with AUD/SUD were significantly less likely to utilize formal substance use than individuals who were White (aOR = 0.28, <em>p</em> &lt; 0.05). There was no significant difference in informal treatment utilization between AA with alcohol use, substance use or AUD/SUD and individuals of any other race/ethnicity. AA with AUD/SUD utilized combined (both informal and formal) services significantly less than individuals who were White (aOR = 0.31, <em>p</em> &lt; 0.05).</div></div><div><h3>Discussion</h3><div>Informal services did not offset the limited substance use treatment engagement in AA. More work is needed to better and understand low rates of substance use treatment in this population.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"177 ","pages":"Article 209754"},"PeriodicalIF":0.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}